根治剂量放疗保膀胱治疗是临床淋巴结阳性非转移性膀胱癌患者根治性膀胱切除术的有效替代方案
这项多中心回顾性分析纳入287例临床淋巴结阳性非转移性膀胱癌患者,比较根治性治疗与姑息治疗及根治性膀胱切除术与根治剂量放疗的生存结局。根治性治疗较姑息治疗改善总生存(HR 0.32,95%CI 0.23-0.44,P<.001);接受根治性治疗的患者中,根治性膀胱切除术与根治剂量放疗的总生存(HR 0.94,95%CI 0.63-1.41,P=.76)和无进展生存(HR 0.74,95%CI 0.50-1.08,P=.12)无显著差异。作者认为保膀胱三联治疗应成为所有临床淋巴结阳性非转移性膀胱癌患者可选的治疗方案。
要点
- 根治性治疗较姑息治疗改善总生存(HR 0.32,95%CI 0.23-0.44,P<.001)。
- 根治性膀胱切除术与根治剂量放疗的总生存无显著差异(HR 0.94,95%CI 0.63-1.41,P=.76)。
- 根治性膀胱切除术与根治剂量放疗的无进展生存无显著差异(HR 0.74,95%CI 0.50-1.08,P=.12)。
核心结论
- 临床淋巴结阳性非转移性膀胱癌患者接受手术或根治性放疗的生存结局相当。
- 鉴于根治性膀胱切除术的已知并发症及该患者群体生存较差,本研究证实保膀胱三联治疗应成为所有临床淋巴结阳性非转移性膀胱癌患者可选的治疗方案。
研究设计与样本
- 多中心回顾性分析,数据来自提供保膀胱三联治疗和根治性膀胱切除术的英国肿瘤中心。
- 共287例临床淋巴结阳性非转移性膀胱癌患者纳入生存分析。
主要发现
- 全部患者中位总生存为1.55年(95%CI 1.35-1.82年)。
- 接受根治性治疗较接受姑息治疗改善总生存(HR 0.32,95%CI 0.23-0.44,P<.001)。
- 接受根治性治疗的患者(n=163)中,76例接受根治性膀胱切除术,87例接受根治剂量放疗。
- 多因素分析中,根治性治疗方式选择与总生存无显著关联(HR 0.94,95%CI 0.63-1.41,P=.76)。
- 多因素分析中,根治性治疗方式选择与无进展生存无显著关联(HR 0.74,95%CI 0.50-1.08,P=.12)。
关键数值与推荐
- 国际指南将保膀胱三联治疗列为根治性膀胱切除术的替代方案。
- 根治性治疗较姑息治疗的总生存HR为0.32(95%CI 0.23-0.44,P<.001)。
- 根治性膀胱切除术与根治剂量放疗的总生存HR为0.94(95%CI 0.63-1.41,P=.76)。
- 根治性膀胱切除术与根治剂量放疗的无进展生存HR为0.74(95%CI 0.50-1.08,P=.12)。
临床怎么用
- 作者认为,保膀胱三联治疗应成为所有临床淋巴结阳性非转移性膀胱癌患者可选的治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bladder-sparing trimodal therapy (TMT) is an alternative to radical cystectomy (RC) according to international guidelines. However, there are limited data to guide management of nonmetastatic clinically node-positive bladder cancer (cN+ M0 BCa). We performed a multicenter retrospective analysis of survival outcomes in node-positive patients to inform practice. METHODS: Data from patients diagnosed with cN+ M0 BCa were collected from participating UK Oncology centers offering both TMT and RC. Overall survival (OS) and progression-free survival (PFS) outcomes were collected with details of treatment and clinical factors. RESULTS: A total of 287 patients with cN+ M0 BCa were included in the survival analysis. Median OS across all patients was 1.55 years (95% CI, 1.35 to 1.82 years). Receiving radical treatments was associated with improved OS (hazard ratio [HR], 0.32; 95% CI, 0.23 to 0.44; P < .001) compared with receiving palliative treatment. Radically treated patients (n = 163) received RC (n = 76) or radical dose radiotherapy (RT, n = 87); choice of radical treatment showed no association with OS (HR, 0.94; 95% CI, 0.63 to 1.41; P = .76) or PFS (HR, 0.74; 95% CI, 0.50 to 1.08; P = .12) on multivariable analysis. CONCLUSION: Patient cohorts with cN+ M0 BCa had equivalent survival outcomes whether treated with surgery or radical RT. Given the known morbidities of RC-in a patient group with poor survival-this study confirms that bladder-sparing TMT treatment should be a treatment option available to all patients with cN+ M0 BCa.
引用
- Swinton M, Mariam NBG, Tan JL, et al. Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer. J Clin Oncol. 2023. PMID: 37478391. doi:10.1200/JCO.23.00725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。